Evolus Inc Stock
€6.20
Your prediction

sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Evolus
sharewise wants to provide you with the best news and tools for Evolus, so we directly link to the best financial data sources.
Financials
News

Evolus Stock: Executives Sell Shares Amid Strong Growth
In March 2025, several top executives at healthcare company Evolus sold significant portions of their company shares through pre-established 10b5-1 trading plans. Director David Moatazedi divested

Evolus (EOLS) Q2 Revenue Rises 4%
Evolus (NASDAQ:EOLS), a performance beauty company specializing in aesthetic neurotoxins and hyaluronic acid (HA) dermal fillers, reported Q2 2025 results on August 5, 2025. The headline news is a